Level Biotechnology (3118) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Level Biotechnology (3118) has a cash flow conversion efficiency ratio of 0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$11.81 Million ≈ $372.24K USD) by net assets (NT$562.82 Million ≈ $17.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Level Biotechnology net asset quality index to measure how much of total assets are equity-financed.
Level Biotechnology - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Level Biotechnology's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 3118 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Level Biotechnology Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Level Biotechnology ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Templeton Emerging Markets Investment Trust TEMIT
LSE:TEM
|
0.003x |
|
WINSON Machinery Co Ltd
TWO:4538
|
0.020x |
|
Impresa - Sociedade Gestora de Participações Sociais S.A
LS:IPR
|
-0.174x |
|
Yellow Balloon Tour Co. Ltd
KQ:104620
|
-0.292x |
|
Sharps Technology Inc
NASDAQ:STSS
|
-0.017x |
|
Kuk Dong
KO:005320
|
-0.103x |
|
Malton Bhd
KLSE:6181
|
-0.051x |
|
QT Imaging Holdings, Inc. Common Stock
NASDAQ:QTI
|
-0.481x |
Annual Cash Flow Conversion Efficiency for Level Biotechnology (2017–2024)
The table below shows the annual cash flow conversion efficiency of Level Biotechnology from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see 3118 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$559.91 Million ≈ $17.64 Million |
NT$64.10 Million ≈ $2.02 Million |
0.114x | -10.41% |
| 2023-12-31 | NT$549.47 Million ≈ $17.31 Million |
NT$70.21 Million ≈ $2.21 Million |
0.128x | +6.51% |
| 2022-12-31 | NT$542.40 Million ≈ $17.09 Million |
NT$65.07 Million ≈ $2.05 Million |
0.120x | -58.09% |
| 2021-12-31 | NT$544.84 Million ≈ $17.17 Million |
NT$155.95 Million ≈ $4.91 Million |
0.286x | +82.08% |
| 2020-12-31 | NT$529.43 Million ≈ $16.68 Million |
NT$83.23 Million ≈ $2.62 Million |
0.157x | -25.92% |
| 2019-12-31 | NT$513.75 Million ≈ $16.19 Million |
NT$109.02 Million ≈ $3.43 Million |
0.212x | +295.34% |
| 2018-12-31 | NT$498.78 Million ≈ $15.71 Million |
NT$26.77 Million ≈ $843.50K |
0.054x | -60.68% |
| 2017-12-31 | NT$522.28 Million ≈ $16.45 Million |
NT$71.29 Million ≈ $2.25 Million |
0.136x | -- |
About Level Biotechnology
Level Biotechnology Inc. engages in marketing and distributing cell culture, immunology, and molecular biology products in Taiwan. It markets and distributes biomedical precision equipment. The company also provides services in the areas of mammalian and genetic toxicology, pharmacology, biocompatibility, and model animal production. In addition, it offers preclinical research services to the bio… Read more